<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0272170" disease_type="Disease or Syndrome" abbrv="">Shwachman-Diamond syndrome</z:e> (<z:chebi fb="26" ids="8984">SDS</z:chebi>) is a rare inherited disorder involving concomitant <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001738'>exocrine pancreatic insufficiency</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>About 25% of patients develop <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a 24-year-old male patient with <z:chebi fb="26" ids="8984">SDS</z:chebi> who underwent allogeneic bone marrow transplantation (BMT) because of progression into <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) following <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The BMT preparative regimen consisted of <z:chebi fb="0" ids="28901">busulfan</z:chebi> (16 mg/kg body wt.), followed by <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (120 mg/kg) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporin A</z:chebi> and short <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were used for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GvHD) prophylaxis </plain></SENT>
<SENT sid="5" pm="."><plain>The post-transplant period was complicated by staphylococcal <z:mpath ids='MPATH_681'>septicemia</z:mpath>, <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e>, <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>, and <z:hpo ids='HP_0011009'>acute</z:hpo> GvHD grade III </plain></SENT>
<SENT sid="6" pm="."><plain>Hematological recovery was delayed (post-transplant day +55) </plain></SENT>
<SENT sid="7" pm="."><plain>The patient was discharged at day +68 in complete remission without any evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>RFLP fingerprint analysis showed complete engraftment of the donor's hematopoiesis </plain></SENT>
<SENT sid="9" pm="."><plain>The patient's <z:hpo ids='HP_0001909'>leukemia</z:hpo> relapsed 9 months post-transplant, and <z:hpo ids='HP_0011420'>death</z:hpo> followed due to <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> and multiorgan failure </plain></SENT>
<SENT sid="10" pm="."><plain>Despite the fatal course in this patient, allogeneic BMT could be an option for curative treatment of the hematopoietic failure in <z:chebi fb="26" ids="8984">SDS</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>The interaction of BMT with <z:e sem="disease" ids="C0030293" disease_type="Disease or Syndrome" abbrv="">pancreatic insufficiency</z:e> still has to be ascertained </plain></SENT>
</text></document>